HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SKB BIO-B

408.800

-2.800-0.68%

Volume:322.20K

Turnover:133.27M

Market Cap:95.33B

PE:-311.35

High:418.600

Open:417.800

Low:408.000

Close:411.600

52wk High:581.000

52wk Low:152.000

Shares:233.19M

HK Float Shares:162.77M

Volume Ratio:0.54

T/O Rate:0.20%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.313

ROE:-17.56%

ROA:-9.92%

PB:17.43

PE(LYR):-311.35

PS:58.23

Loading ...

Overview Company News Filings

Sichuan KelunBiotech Biopharmaceutical receives NMPA approval for sacituzumab tirumotecan in EGFR mutant NSCLC after EGFR TKI therapy

SKB BIO-B (06990): Core Product TROP2-ADC Sacituzumab Govitecan (SAC-TMT) Receives NMPA Approval for Third Indication to Treat EGFR-Mutated Non-Small Cell Lung Cancer Following EGFR-TKI Treatment Progression

Sichuan Kelun Biotech receives NMPA approval for third indication of TROP2 ADC sac TMT in EGFR mutant NSCLC after EGFR TKI therapy

CICC: Optimistic About Long-term Development Trends in Innovative Pharmaceuticals, Anticipates Commercial Insurance Breakthrough

Chinese Pharmaceutical Stocks Drop as Investors Take Profit -- Market Talk

Tianfeng Securities Upgrades SKB BIO-B (06990) Rating to "Buy" as Core Product Commercialization Progresses Smoothly

3 Asian Stocks That May Be Priced Below Their True Value In October 2025

Simply Wall St.

BRIEF-Sichuan Kelun-Biotech Biopharmaceutical To Subscribe For BOC Structured Deposit At Principal Amount Of RMB440 Million

SKB BIO-B (06990) Subscribes to RMB 440 Million Bank of China Structured Deposits

Sichuan Kelun-Biotech Biopharmaceutical - Co to Subscribe for BOC Structured Deposi at Principal Amount of RMB440 Mln

THOMSON REUTERS

BOCOM International: Trump's Drug Tariffs Have Limited Impact on Chinese Pharmaceuticals, Recommends Focus on AKESO (09926) and Others

Innovative Drug Industry Trend Established, Advancing Global Commercialization

Sichuan Kelun-Biotech Biopharmaceutical First Half 2025 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

SKB BIO-B (06990): New Drug Application for A400/EP0031 Accepted by National Medical Products Administration

Sichuan Kelun-Biotech Announces New Drug Application for A400/EP0031 Accepted for Review by China's National Medical Products Administration

Sichuan Kelun-Biotech Biopharmaceutical - New Drug Application for a400/Ep0031 Accepted for Review by Nmpa China

THOMSON REUTERS

SKB Biopharma Approves Hong Kong-Listed Share Full Circulation

MT Newswires Live

SKB BIO-B (06990) Plans to Implement H-Share Full Circulation Scheme

GF Securities: Industry's Medium to Long-term Positive Trend Established, BD Deals Are Just the Starting Point of This Round of Innovative Drug Value Revaluation

Hong Kong Stock Concept Tracking | MSCI Index Adjustments Take Effect Tomorrow After Market Close! Tech Stocks and Others May Welcome Incremental Funds as Foreign Capital Collectively Turns Bullish on Chinese Assets (With Concept Stocks)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/06990/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06990","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"SKB BIO-B","latestPrice":408.8,"timestamp":1762494964987,"preClose":411.6,"halted":0,"volume":322200,"delay":0,"floatShares":162769979,"shares":233185969,"eps":-1.3129828118065978,"marketStatus":"Trading","change":-2.8,"latestTime":"11-07 13:56:10","open":417.8,"high":418.6,"low":408,"amount":133265548,"amplitude":0.025753,"askPrice":408.8,"askSize":1500,"bidPrice":408.6,"bidSize":1200,"shortable":3,"etf":0,"ttmEps":-3.4932576227424335,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1762503000000},"marketStatusCode":2,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":411.6,"openAndCloseTimeList":[[1762479000000,1762488000000],[1762491600000,1762502400000]],"volumeRatio":0.540644,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","floatShares":162769979,"roa":"-9.92%","roe":"-17.56%","lyrEps":-1.312983,"volumeRatio":0.540644,"shares":233185969,"dividePrice":0,"high":418.6,"amplitude":0.025753,"preClose":411.6,"low":408,"week52Low":152,"pbRate":"17.43","psRate":"58.23","week52High":581,"institutionHeld":0,"latestPrice":408.8,"committee":-0.111111,"eps":-1.3129828118065978,"divideRate":0,"volume":322200,"delay":0,"ttmEps":-3.4932576227424335,"open":417.8,"prevYearClose":163.3,"prevWeekClose":448,"prevMonthClose":448,"prevQuarterClose":514,"fiveDayClose":448,"twentyDayClose":510.5,"sixtyDayClose":403.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06990\",params:#limit:5,,,undefined,":[{"date":"2025-08-18","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755480600000,"name":null,"time":"","dateTimestamp":1755446400000,"actualEps":null},{"date":"2025-03-24","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"Post Market","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-19","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724031000000,"name":null,"time":"Post Market","dateTimestamp":1723996800000,"actualEps":null},{"date":"2024-03-25","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null},{"date":"2023-08-28","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693186200000,"name":null,"time":"","dateTimestamp":1693152000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06990\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06990\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.5556,"hold":0.1111,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5556,"analysts":18,"updateTime":1755619200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06990\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06990","date":"2025-11-06","current":-118.161458,"percent":0.52,"low":-351.800852,"twenty":-203.932949,"median":-132.129081,"eighty":-48.609184,"high":-21.029201,"avg":-126.795211,"sd":82.579441,"marketCap":95979344840},"quantilePoints":[{"date":"2023-07-14","current":-21.13661,"twenty":-21.950454,"median":-21.915957,"eighty":-21.591449,"marketCap":14244687534},{"date":"2023-07-21","current":-23.970152,"twenty":-21.950454,"median":-21.798359,"eighty":-21.186829,"marketCap":16079230625},{"date":"2023-07-28","current":-25.171471,"twenty":-24.928642,"median":-21.953758,"eighty":-21.326081,"marketCap":16867005011},{"date":"2023-08-04","current":-23.795235,"twenty":-24.81024,"median":-23.425444,"eighty":-21.637654,"marketCap":15971316326},{"date":"2023-08-11","current":-25.354634,"twenty":-24.81024,"median":-23.323535,"eighty":-21.856149,"marketCap":16921892522},{"date":"2023-08-18","current":-27.290696,"twenty":-25.136334,"median":-23.811022,"eighty":-21.920213,"marketCap":18083628667},{"date":"2023-08-25","current":-27.955027,"twenty":-25.91111,"median":-24.066367,"eighty":-21.957062,"marketCap":18532979440},{"date":"2023-09-01","current":-41.23344,"twenty":-27.36684,"median":-24.766756,"eighty":-21.989236,"marketCap":16768455673},{"date":"2023-09-08","current":-41.179226,"twenty":-40.625811,"median":-24.994187,"eighty":-22.159386,"marketCap":16549260174},{"date":"2023-09-15","current":-42.756679,"twenty":-41.200358,"median":-25.354634,"eighty":-22.761005,"marketCap":17316444421},{"date":"2023-09-22","current":-42.808543,"twenty":-42.12743,"median":-25.915972,"eighty":-23.169807,"marketCap":17261645546},{"date":"2023-09-29","current":-41.568511,"twenty":-42.347449,"median":-27.197776,"eighty":-23.343916,"marketCap":16790375223},{"date":"2023-10-06","current":-41.914184,"twenty":-42.346401,"median":-27.481057,"eighty":-23.57336,"marketCap":16921892522},{"date":"2023-10-13","current":-45.021843,"twenty":-42.393899,"median":-34.166325,"eighty":-23.80155,"marketCap":18149387317},{"date":"2023-10-20","current":-39.509362,"twenty":-42.529229,"median":-40.304828,"eighty":-23.874674,"marketCap":15902633452},{"date":"2023-10-27","current":-41.923505,"twenty":-42.45246,"median":-40.317099,"eighty":-23.977981,"marketCap":16867093648},{"date":"2023-11-03","current":-44.17615,"twenty":-43.157759,"median":-40.968576,"eighty":-24.032126,"marketCap":17820594068},{"date":"2023-11-10","current":-48.451746,"twenty":-43.729096,"median":-41.213927,"eighty":-24.147781,"marketCap":19541278735},{"date":"2023-11-17","current":-48.422639,"twenty":-44.163404,"median":-41.246315,"eighty":-24.349478,"marketCap":19705675360},{"date":"2023-11-24","current":-47.973827,"twenty":-44.628759,"median":-41.529173,"eighty":-24.780872,"marketCap":19683755810},{"date":"2023-12-01","current":-50.941262,"twenty":-45.174782,"median":-41.90853,"eighty":-24.844962,"marketCap":20987969029},{"date":"2023-12-08","current":-50.880899,"twenty":-46.685504,"median":-41.9817,"eighty":-24.922954,"marketCap":20878371279},{"date":"2023-12-15","current":-53.058458,"twenty":-47.438439,"median":-42.172758,"eighty":-25.124621,"marketCap":21897630350},{"date":"2023-12-22","current":-55.272951,"twenty":-48.26932,"median":-42.355666,"eighty":-25.208104,"marketCap":22796331896},{"date":"2023-12-29","current":-54.398289,"twenty":-48.483234,"median":-42.389893,"eighty":-25.318001,"marketCap":22555216847},{"date":"2024-01-05","current":-54.305497,"twenty":-48.692055,"median":-42.518207,"eighty":-25.505631,"marketCap":22357940898},{"date":"2024-01-12","current":-58.852865,"twenty":-49.706536,"median":-42.808543,"eighty":-25.777515,"marketCap":24243022189},{"date":"2024-01-19","current":-48.649703,"twenty":-50.614438,"median":-43.44751,"eighty":-25.920835,"marketCap":20012549058},{"date":"2024-01-26","current":-45.202208,"twenty":-50.432693,"median":-43.523908,"eighty":-26.320623,"marketCap":18522019665},{"date":"2024-02-02","current":-38.832469,"twenty":-50.323187,"median":-43.65215,"eighty":-26.948338,"marketCap":15891673677},{"date":"2024-02-09","current":-43.972121,"twenty":-49.706536,"median":-43.780393,"eighty":-27.253528,"marketCap":18083628667},{"date":"2024-02-16","current":-51.156498,"twenty":-50.095577,"median":-43.99523,"eighty":-27.328768,"marketCap":21042767904},{"date":"2024-02-23","current":-57.052501,"twenty":-50.855188,"median":-44.095348,"eighty":-27.575851,"marketCap":23344320643},{"date":"2024-03-01","current":-55.517903,"twenty":-51.144997,"median":-44.174132,"eighty":-27.979787,"marketCap":22730573246},{"date":"2024-03-08","current":-62.556972,"twenty":-52.587613,"median":-44.308071,"eighty":-30.229554,"marketCap":25623953833},{"date":"2024-03-15","current":-80.340969,"twenty":-54.14227,"median":-44.794506,"eighty":-38.844663,"marketCap":32879324850},{"date":"2024-03-22","current":-87.812662,"twenty":-54.39157,"median":-45.089055,"eighty":-38.957109,"marketCap":35904222736},{"date":"2024-03-28","current":-54.646477,"twenty":-54.498503,"median":-45.202208,"eighty":-39.211798,"marketCap":33975302345},{"date":"2024-04-05","current":-48.790889,"twenty":-54.557693,"median":-45.399289,"eighty":-39.390336,"marketCap":30314737511},{"date":"2024-04-12","current":-51.407626,"twenty":-54.48688,"median":-46.006494,"eighty":-39.95604,"marketCap":31958703754},{"date":"2024-04-19","current":-48.134373,"twenty":-54.430626,"median":-46.386128,"eighty":-40.284427,"marketCap":29898266063},{"date":"2024-04-26","current":-71.709655,"twenty":-54.881886,"median":-46.751052,"eighty":-40.312191,"marketCap":36824843832},{"date":"2024-05-03","current":-70.050704,"twenty":-55.277405,"median":-46.894686,"eighty":-40.440284,"marketCap":35948061836},{"date":"2024-05-10","current":-80.537958,"twenty":-55.535893,"median":-47.299854,"eighty":-40.706984,"marketCap":41427949311},{"date":"2024-05-17","current":-72.846762,"twenty":-56.640749,"median":-47.434905,"eighty":-40.885351,"marketCap":37416671679},{"date":"2024-05-24","current":-76.490072,"twenty":-57.838988,"median":-47.480121,"eighty":-41.121673,"marketCap":39198277014},{"date":"2024-05-31","current":-74.804992,"twenty":-59.45269,"median":-48.0541,"eighty":-41.186166,"marketCap":38373753847},{"date":"2024-06-07","current":-77.551054,"twenty":-62.567703,"median":-48.422639,"eighty":-41.217553,"marketCap":39733102851},{"date":"2024-06-14","current":-71.048454,"twenty":-63.220056,"median":-48.609184,"eighty":-41.232055,"marketCap":36368156956},{"date":"2024-06-21","current":-75.38559,"twenty":-65.709636,"median":-48.654461,"eighty":-41.23344,"marketCap":38507460307},{"date":"2024-06-28","current":-72.361795,"twenty":-70.050704,"median":-48.790889,"eighty":-41.25919,"marketCap":36947551614},{"date":"2024-07-05","current":-71.32983,"twenty":-70.110492,"median":-48.913989,"eighty":-41.293743,"marketCap":36412725776},{"date":"2024-07-12","current":-64.338068,"twenty":-69.786991,"median":-49.290918,"eighty":-41.483815,"marketCap":32891789012},{"date":"2024-07-19","current":-64.816339,"twenty":-69.10708,"median":-50.290098,"eighty":-41.560643,"marketCap":33136917521},{"date":"2024-07-26","current":-64.836994,"twenty":-68.943217,"median":-50.396598,"eighty":-41.836002,"marketCap":33270623980},{"date":"2024-08-02","current":-67.177788,"twenty":-68.832021,"median":-50.583009,"eighty":-41.911922,"marketCap":34451697705},{"date":"2024-08-09","current":-67.337335,"twenty":-68.832021,"median":-50.91108,"eighty":-41.921641,"marketCap":34763679444},{"date":"2024-08-16","current":-69.468586,"twenty":-68.832021,"median":-51.098991,"eighty":-41.970061,"marketCap":35877899939},{"date":"2024-08-23","current":-143.952492,"twenty":-69.519081,"median":-51.282062,"eighty":-42.023931,"marketCap":36568716645},{"date":"2024-08-30","current":-142.905377,"twenty":-70.543671,"median":-51.775379,"eighty":-42.069838,"marketCap":36546432236},{"date":"2024-09-06","current":-147.713941,"twenty":-71.622574,"median":-52.451442,"eighty":-42.229208,"marketCap":37794359190},{"date":"2024-09-13","current":-159.71572,"twenty":-72.235174,"median":-53.058458,"eighty":-42.319371,"marketCap":40758185707},{"date":"2024-09-20","current":-153.295015,"twenty":-72.624329,"median":-53.663008,"eighty":-42.346401,"marketCap":39354267883},{"date":"2024-09-27","current":-152.378595,"twenty":-73.54444,"median":-54.299669,"eighty":-42.364187,"marketCap":39354267883},{"date":"2024-10-04","current":-188.785359,"twenty":-74.133327,"median":-54.381491,"eighty":-42.385888,"marketCap":48535444762},{"date":"2024-10-10","current":-168.292174,"twenty":-74.96999,"median":-54.488817,"eighty":-42.420555,"marketCap":42986626697},{"date":"2024-10-18","current":-169.261982,"twenty":-75.395206,"median":-54.742682,"eighty":-42.48514,"marketCap":43008911107},{"date":"2024-10-25","current":-173.131782,"twenty":-76.300948,"median":-55.181976,"eighty":-42.60999,"marketCap":43989425142},{"date":"2024-11-01","current":-155.135166,"twenty":-77.964709,"median":-55.298647,"eighty":-42.767052,"marketCap":39443405523},{"date":"2024-11-08","current":-154.553256,"twenty":-78.843611,"median":-55.532894,"eighty":-42.819467,"marketCap":38997717325},{"date":"2024-11-15","current":-143.716763,"twenty":-80.792913,"median":-56.569783,"eighty":-42.897746,"marketCap":35989321988},{"date":"2024-11-22","current":-149.571879,"twenty":-86.542136,"median":-57.071537,"eighty":-43.077872,"marketCap":37437808632},{"date":"2024-11-29","current":-163.214034,"twenty":-139.660525,"median":-57.926605,"eighty":-43.27892,"marketCap":40825038936},{"date":"2024-12-06","current":-164.492389,"twenty":-143.07608,"median":-58.601892,"eighty":-43.427612,"marketCap":41047883035},{"date":"2024-12-13","current":-167.859925,"twenty":-143.961595,"median":-59.46824,"eighty":-43.489321,"marketCap":41805552972},{"date":"2024-12-20","current":-160.518216,"twenty":-146.054141,"median":-61.493522,"eighty":-43.569737,"marketCap":39799956081},{"date":"2024-12-27","current":-154.616488,"twenty":-147.398806,"median":-62.556972,"eighty":-43.707223,"marketCap":38306900618},{"date":"2025-01-03","current":-146.467928,"twenty":-147.580179,"median":-62.909234,"eighty":-43.769457,"marketCap":36323588137},{"date":"2025-01-10","current":-149.189796,"twenty":-147.713941,"median":-63.270129,"eighty":-43.89543,"marketCap":36858413974},{"date":"2025-01-17","current":-146.545949,"twenty":-148.128618,"median":-63.821936,"eighty":-43.999852,"marketCap":36234450497},{"date":"2025-01-24","current":-151.096908,"twenty":-148.795989,"median":-64.223738,"eighty":-44.022873,"marketCap":37593799501},{"date":"2025-01-28","current":-144.751587,"twenty":-148.750633,"median":-64.3181,"eighty":-44.025895,"marketCap":36203787461},{"date":"2025-02-07","current":-162.755483,"twenty":-148.864023,"median":-64.816339,"eighty":-44.095348,"marketCap":40476425278},{"date":"2025-02-14","current":-166.856795,"twenty":-150.654332,"median":-65.202788,"eighty":-44.112421,"marketCap":41476404342},{"date":"2025-02-21","current":-194.414734,"twenty":-151.676932,"median":-65.382992,"eighty":-44.172115,"marketCap":48498984584},{"date":"2025-02-28","current":-211.14481,"twenty":-152.24965,"median":-65.712478,"eighty":-44.17615,"marketCap":52498900839},{"date":"2025-03-07","current":-225.41295,"twenty":-152.905086,"median":-66.309677,"eighty":-44.219461,"marketCap":56271549124},{"date":"2025-03-14","current":-227.151092,"twenty":-153.295015,"median":-66.812487,"eighty":-44.308071,"marketCap":56726085062},{"date":"2025-03-21","current":-236.708664,"twenty":-154.553256,"median":-67.337335,"eighty":-44.550078,"marketCap":59089671940},{"date":"2025-03-28","current":-231.805328,"twenty":-155.61149,"median":-67.803663,"eighty":-44.648429,"marketCap":66180441600},{"date":"2025-04-03","current":-246.46154,"twenty":-156.727441,"median":-67.952396,"eighty":-44.882152,"marketCap":70225812000},{"date":"2025-04-11","current":-242.489155,"twenty":-158.779779,"median":-68.515098,"eighty":-45.005591,"marketCap":68634936000},{"date":"2025-04-17","current":-228.611836,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"marketCap":64862287200},{"date":"2025-04-25","current":-235.137362,"twenty":-160.624501,"median":-68.953584,"eighty":-45.131919,"marketCap":66771338400},{"date":"2025-05-02","current":-274.570331,"twenty":-161.195254,"median":-69.468586,"eighty":-45.197413,"marketCap":78134738400},{"date":"2025-05-09","current":-249.374354,"twenty":-161.514906,"median":-70.050704,"eighty":-45.202208,"marketCap":71462875059},{"date":"2025-05-16","current":-247.507619,"twenty":-162.87029,"median":-70.732965,"eighty":-45.217068,"marketCap":71507400214},{"date":"2025-05-23","current":-244.618313,"twenty":-163.824551,"median":-71.32983,"eighty":-45.58151,"marketCap":70884048033},{"date":"2025-05-30","current":-244.159494,"twenty":-165.025774,"median":-71.669987,"eighty":-45.601984,"marketCap":71062148656},{"date":"2025-06-06","current":-258.187076,"twenty":-166.004403,"median":-72.203519,"eighty":-46.006494,"marketCap":75336563613},{"date":"2025-06-13","current":-271.678883,"twenty":-167.701589,"median":-72.488214,"eighty":-46.133909,"marketCap":79304691313},{"date":"2025-06-20","current":-252.757485,"twenty":-168.349452,"median":-72.789206,"eighty":-46.315126,"marketCap":73636805593},{"date":"2025-06-27","current":-255.806605,"twenty":-169.647858,"median":-73.569836,"eighty":-46.457129,"marketCap":74733815733},{"date":"2025-07-04","current":-283.173205,"twenty":-171.495185,"median":-73.869687,"eighty":-46.685504,"marketCap":82732847998},{"date":"2025-07-11","current":-266.231967,"twenty":-173.142078,"median":-74.539848,"eighty":-46.749361,"marketCap":77704884860},{"date":"2025-07-18","current":-304.526119,"twenty":-187.755426,"median":-75.01675,"eighty":-46.798833,"marketCap":88812112519},{"date":"2025-07-25","current":-289.211949,"twenty":-196.095673,"median":-75.38559,"eighty":-46.877904,"marketCap":84652615741},{"date":"2025-08-01","current":-318.351212,"twenty":-209.071662,"median":-75.715906,"eighty":-46.908544,"marketCap":92605939250},{"date":"2025-08-08","current":-315.832709,"twenty":-214.487876,"median":-76.34536,"eighty":-47.149906,"marketCap":92103142937},{"date":"2025-08-15","current":-340.637946,"twenty":-221.73884,"median":-77.157567,"eighty":-47.354138,"marketCap":99188000086},{"date":"2025-08-22","current":-135.707825,"twenty":-221.73884,"median":-78.335478,"eighty":-47.421279,"marketCap":106638527281},{"date":"2025-08-29","current":-131.473703,"twenty":-217.466422,"median":-78.819337,"eighty":-47.438439,"marketCap":103804584421},{"date":"2025-09-05","current":-151.82862,"twenty":-215.82299,"median":-80.340969,"eighty":-47.449348,"marketCap":119756940196},{"date":"2025-09-12","current":-146.494298,"twenty":-214.791029,"median":-81.555855,"eighty":-47.474394,"marketCap":115757424063},{"date":"2025-09-19","current":-147.466634,"twenty":-214.487876,"median":-85.53437,"eighty":-47.73502,"marketCap":116443055400},{"date":"2025-09-26","current":-143.954691,"twenty":-214.295448,"median":-89.950081,"eighty":-47.938811,"marketCap":113375018127},{"date":"2025-10-03","current":-165.853778,"twenty":-213.463042,"median":-128.34687,"eighty":-48.070155,"marketCap":130933921593},{"date":"2025-10-10","current":-144.531455,"twenty":-212.219938,"median":-131.729362,"eighty":-48.217901,"marketCap":113934664453},{"date":"2025-10-17","current":-135.703716,"twenty":-210.108236,"median":-132.867642,"eighty":-48.374971,"marketCap":106892448189},{"date":"2025-10-24","current":-129.499037,"twenty":-207.014216,"median":-133.546653,"eighty":-48.434282,"marketCap":102042180034},{"date":"2025-10-31","current":-132.379263,"twenty":-204.550971,"median":-132.326202,"eighty":-48.483234,"marketCap":104467314112},{"date":"2025-11-06","current":-121.699468,"twenty":-203.932949,"median":-132.129081,"eighty":-48.609184,"marketCap":95979344840}],"updateTime":1762479294226},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06990\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2574492655","title":"Sichuan KelunBiotech Biopharmaceutical receives NMPA approval for sacituzumab tirumotecan in EGFR mutant NSCLC after EGFR TKI therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2574492655","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574492655?lang=en_us&edition=fundamental","pubTime":"2025-10-12 18:41","pubTimestamp":1760265675,"startTime":"0","endTime":"0","summary":"Sichuan KelunBiotech Biopharmaceutical receives NMPA approval for sacituzumab tirumotecan in EGFR mutant NSCLC after EGFR TKI therapy. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that its core product, sacituzumab tirumotecan , has been approved for marketing by the National Medical Products Administration  in China. This approval covers a third indication: the treatment of adult patients with epidermal growth factor receptor  mutant-positive locally advanced or metastatic non-squamous non-small cell lung cancer  who have progressed after EGFR-tyrosine kinase inhibitor  therapy. The company continues to pursue regulatory review for additional indications, with several clinical studies ongoing. No grant or funding by multiple organizations was mentioned in the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251012:nNDLc6tMLH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2148510915.USD","002422","LU1064131003.USD","LU1934453819.USD","LU1979443071.USD","LU1064130708.USD","06990","BK0060","BK0239","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"1169322208","title":"SKB BIO-B (06990): Core Product TROP2-ADC Sacituzumab Govitecan (SAC-TMT) Receives NMPA Approval for Third Indication to Treat EGFR-Mutated Non-Small Cell Lung Cancer Following EGFR-TKI Treatment Progression","url":"https://stock-news.laohu8.com/highlight/detail?id=1169322208","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169322208?lang=en_us&edition=fundamental","pubTime":"2025-10-12 18:38","pubTimestamp":1760265506,"startTime":"0","endTime":"0","summary":"SKB BIO-B (06990) announced that its antibody-drug conjugate (ADC) targeting human trophoblast cell surface antigen 2 (TROP2), sacituzumab govitecan (sac-TMT, also known as SKB264/MK-2870, brand name...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2574669437","title":"Sichuan Kelun Biotech receives NMPA approval for third indication of TROP2 ADC sac TMT in EGFR mutant NSCLC after EGFR TKI therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2574669437","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574669437?lang=en_us&edition=fundamental","pubTime":"2025-10-11 17:35","pubTimestamp":1760175358,"startTime":"0","endTime":"0","summary":"Sichuan Kelun Biotech receives NMPA approval for third indication of TROP2 ADC sac TMT in EGFR mutant NSCLC after EGFR TKI therapy. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced that its TROP2-directed antibody-drug conjugate, sacituzumab tirumotecan , has received marketing approval from the National Medical Products Administration  for its third indication. The newly approved use is for the treatment of adult patients with EGFR mutant-positive locally advanced or metastatic non-squamous non-small cell lung cancer  who have progressed after EGFR-tyrosine kinase inhibitor  therapy. This approval is based on positive results from the Phase III OptiTROP-Lung04 study, which demonstrated significant improvements in overall survival and progression-free survival compared to platinum-based chemotherapy in this patient population. No grant or funding information involving multiple organizations was mentioned.Disclaimer: This news brief was created by Public Technologies  usi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251011:nNDL3GwrLK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064130708.USD","LU1934453819.USD","BK0239","002422","BK1161","BK0060","LU1064131003.USD","LU1979443071.USD","LU0196878994.USD","06990","LU2148510915.USD"],"gpt_icon":0},{"id":"1167173786","title":"CICC: Optimistic About Long-term Development Trends in Innovative Pharmaceuticals, Anticipates Commercial Insurance Breakthrough","url":"https://stock-news.laohu8.com/highlight/detail?id=1167173786","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167173786?lang=en_us&edition=fundamental","pubTime":"2025-10-09 16:08","pubTimestamp":1759997323,"startTime":"0","endTime":"0","summary":"CICC released a research report stating that with the support of domestic engineering talent dividends, abundant clinical resources, and supportive policies, domestic innovative drugs have gradually...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093","LU1951186391.HKD","LU1008478684.HKD","IE0008369823.USD","BK1521","LU0501845795.SGD","LU0067412154.USD","LU0315179316.USD","LU0314109678.HKD","IE00BZ08YS42.EUR","01177","LU1960683339.HKD","IE00B543WZ88.USD","LU1226287529.USD","IE0008368742.USD","159992","BK1161","LU0326950275.SGD","LU1152091754.HKD","LU1226287875.USD","BK1589","LU1152091168.USD","BK1574","IE00BZ08YR35.GBP","LU1328277881.USD","LU1807302812.USD","BK1515","06990","IE00B031HY20.USD","LU1226288253.USD","LU1813983027.USD","LU1993786604.SGD","LU1226288170.HKD","LU0140636845.USD","IE00BZ08YT58.USD","LU0072913022.USD","LU0880133367.SGD","IE00B5MMRT66.SGD","SG9999004220.SGD","LU1226287792.SGD","LU0196878994.USD","BK1191","LU2039709279.SGD","06978"],"gpt_icon":0},{"id":"2574189677","title":"Chinese Pharmaceutical Stocks Drop as Investors Take Profit -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2574189677","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574189677?lang=en_us&edition=fundamental","pubTime":"2025-10-09 12:00","pubTimestamp":1759982400,"startTime":"0","endTime":"0","summary":"0400 GMT - Chinese pharmaceutical stocks weaken in Hong Kong, likely to due to profit-taking. Sichuan Kelun-Biotech Biopharmaceutical is down 8.1%, Simcere Pharmaceutical Group declines 3.7% and CSPC Pharmaceutical Group is 2.85% lower. \"Overall it's profit-taking and possibly rotation to tech [stocks] after a massive rally year-to-date,\" said Jefferies' Cui Cui. China's pharmaceutical stocks have enjoyed a strong rally this year, with Sichuan Kelun rising more than 200% since the beginning of the year. CSPC's shares have nearly doubled and Simcere's shares are up 80% year to date. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ISBC","BK1583","IE00B543WZ88.USD","LU0314109678.HKD","LU1328277881.USD","LU0067412154.USD","BK1191","LU1152091754.HKD","BK1161","LU1226287792.SGD","LU1951186391.HKD","LU2039709279.SGD","LU0501845795.SGD","LU0315179316.USD","IE0008368742.USD","06990","LU1226288170.HKD","LU1008478684.HKD","BK1515","LU0326950275.SGD","LU1813983027.USD","LU0196878994.USD","01093","BK1521","LU0880133367.SGD","IE00BZ08YS42.EUR","LU1226287529.USD","LU0072913022.USD","SG9999004220.SGD","LU0140636845.USD","LU1226287875.USD","LU1993786604.SGD","BK4211","IE00BZ08YT58.USD","LU1807302812.USD","IE00B5MMRT66.SGD","LU1152091168.USD","LU1226288253.USD","IE0008369823.USD","02096","IE00B031HY20.USD","IE00BZ08YR35.GBP","LU1960683339.HKD"],"gpt_icon":0},{"id":"1199395913","title":"Tianfeng Securities Upgrades SKB BIO-B (06990) Rating to \"Buy\" as Core Product Commercialization Progresses Smoothly","url":"https://stock-news.laohu8.com/highlight/detail?id=1199395913","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199395913?lang=en_us&edition=fundamental","pubTime":"2025-10-09 09:48","pubTimestamp":1759974516,"startTime":"0","endTime":"0","summary":"Tianfeng Securities Co.,Ltd. issued a research report stating that the NMPA recently approved the additional 100mg specification for SKB BIO-B's (06990) SKB264, which will further optimize clinical...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601162","BK0276","LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2572562337","title":"3 Asian Stocks That May Be Priced Below Their True Value In October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2572562337","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572562337?lang=en_us&edition=fundamental","pubTime":"2025-10-02 06:04","pubTimestamp":1759356259,"startTime":"0","endTime":"0","summary":"As global markets navigate a complex landscape marked by cautious monetary policies and fluctuating economic indicators, Asia's stock markets present intriguing opportunities for investors. In this context, identifying stocks that may be undervalued involves assessing companies with strong fundamentals that are not fully reflected in their current market prices.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/5221000-choice2-main-header/1585186851278","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5221000-choice2-main-header/1585186851278"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/household/hkg-2367/giant-biogene-holding-shares/news/3-asian-stocks-that-may-be-priced-below-their-true-value-in","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/household/hkg-2367/giant-biogene-holding-shares/news/3-asian-stocks-that-may-be-priced-below-their-true-value-in","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2571334545","title":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical To Subscribe For BOC Structured Deposit At Principal Amount Of RMB440 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2571334545","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571334545?lang=en_us&edition=fundamental","pubTime":"2025-09-29 21:58","pubTimestamp":1759154326,"startTime":"0","endTime":"0","summary":"BRIEF-Sichuan Kelun-Biotech Biopharmaceutical To Subscribe For BOC Structured Deposit At Principal Amount Of RMB440 MillionSept 29  - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:CO TO SUBSCRIBE FOR BOC STRUCTURED DEPOSIT AT PRINCIPAL AMOUNT OF RMB440 MILLIONFurther company coverage: 6990.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nFWN3VG0JO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"1123817386","title":"SKB BIO-B (06990) Subscribes to RMB 440 Million Bank of China Structured Deposits","url":"https://stock-news.laohu8.com/highlight/detail?id=1123817386","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123817386?lang=en_us&edition=fundamental","pubTime":"2025-09-29 21:08","pubTimestamp":1759151325,"startTime":"0","endTime":"0","summary":"SKB BIO-B (06990) announced that on September 29, 2025, the company entered into a structured deposit agreement with Bank of China, pursuant to which the company agreed to subscribe to Bank of China...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001093.SGD","BK0012","601988","BK0015","LU0307460666.USD","LU1497733631.SGD","BK1560","BK0278","LU2097828474.EUR","LU2097828805.USD","LU1282651048.USD","BK0183","SG9999006597.SGD","LU0651947912.USD","03143","LU1634259557.SGD","LU2097828631.EUR","LU2097828557.USD","BK1231","LU0651946864.USD","IE00BWDBJ730.SGD","LU0293314216.USD","LU1051769294.HKD","LU0348805143.USD","BK0028","LU1048588211.SGD","LU0588546209.SGD","LU1051768304.USD","LU1282651121.HKD","LU1515016050.SGD","BK0188","BK1161","LU2097828714.EUR","03988","LU1522347837.USD","BK1521","LU1224444064.USD","LU0072462343.USD","IE00BQJZWZ67.USD","LU0196878994.USD","06990","LU1497733557.USD","LU1497734951.SGD","LU1634259391.SGD","IE00B19Z5X02.USD"],"gpt_icon":0},{"id":"2571336685","title":"Sichuan Kelun-Biotech Biopharmaceutical - Co to Subscribe for BOC Structured Deposi at Principal Amount of RMB440 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2571336685","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571336685?lang=en_us&edition=fundamental","pubTime":"2025-09-29 20:57","pubTimestamp":1759150657,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nFWN3VG0JO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"1167469646","title":"BOCOM International: Trump's Drug Tariffs Have Limited Impact on Chinese Pharmaceuticals, Recommends Focus on AKESO (09926) and Others","url":"https://stock-news.laohu8.com/highlight/detail?id=1167469646","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167469646?lang=en_us&edition=fundamental","pubTime":"2025-09-29 11:50","pubTimestamp":1759117844,"startTime":"0","endTime":"0","summary":"BOCOM International released a research report stating that Trump announced a 100% tariff on all branded/patented drugs starting in October, unless the manufacturer is constructing production...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348827113.USD","LU0561508036.HKD","09995","BK1574","06996","06990","BK0250","BK1191","LU0348735423.USD","LU1794554557.SGD","BK0010","BK1161","LU2399975544.HKD","BK0175","LU1969619763.USD","IE00BPRC5H50.USD","LU0348766576.USD","LU0417516571.SGD","600056","IE00B543WZ88.USD","03329","BK1583","LU0634319403.HKD","LU2476274720.SGD","BK0082","LU0348767384.USD","LU0540923850.HKD","LU0196878994.USD","BK0188","LU0417516902.SGD","LU0348783233.USD","LU0348784397.USD","IE00B5MMRT66.SGD","LU0417516738.SGD","LU0348825331.USD","LU2488822045.USD","BK0185","LU2328871848.SGD","09926","02096","LU1961090484.USD","LU2778985437.USD","BK0028","LU2476274308.USD","LU1720050803.USD","BK1593","01530","BK1147"],"gpt_icon":0},{"id":"1152572190","title":"Innovative Drug Industry Trend Established, Advancing Global Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=1152572190","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152572190?lang=en_us&edition=fundamental","pubTime":"2025-09-24 08:12","pubTimestamp":1758672755,"startTime":"0","endTime":"0","summary":"A research report indicates that China's innovative drug sector has established a pyramid-like structure led by frontrunner companies and supported by numerous high-quality enterprises, demonstrating...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","LU0307460666.USD","LU0348825331.USD","LU2097828474.EUR","BK1500","LU0634319403.HKD","601162","LU2097828805.USD","LU0348827113.USD","LU0348766576.USD","LU1719994722.HKD","BK1593","LU0502904849.HKD","LU0348783233.USD","BK0276","BK1588","BK1589","LU1969619763.USD","IE00B5MMRT66.SGD","LU1303224171.USD","LU0417516738.SGD","LU2097828631.EUR","LU2097828557.USD","LU2488822045.USD","LU2476274720.SGD","LU1720050803.USD","LU0417516902.SGD","LU2476274308.USD","LU2778985437.USD","01801","LU0455707207.USD","LU2242644610.SGD","IE00BPRC5H50.USD","159992","IE00B543WZ88.USD","BK1574","LU0348767384.USD","LU0561508036.HKD","LU0588546209.SGD","LU0540923850.HKD","BK1161","LU1794554557.SGD","BK1583","LU0348735423.USD","01530","LU1251922891.USD","LU2097828714.EUR","LU0196878994.USD","LU2328871848.SGD","06990","LU1770034418.SGD","LU0348784397.USD","LU0417516571.SGD","06978","09926"],"gpt_icon":0},{"id":"2569724825","title":"Sichuan Kelun-Biotech Biopharmaceutical First Half 2025 Earnings: EPS Beats Expectations, Revenues Lag","url":"https://stock-news.laohu8.com/highlight/detail?id=2569724825","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569724825?lang=en_us&edition=fundamental","pubTime":"2025-09-24 07:48","pubTimestamp":1758671293,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical ( HKG:6990 ) First Half 2025 Results Key Financial Results Revenue: CN¥950.4m...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/sichuan-kelun-biotech-biopharmaceutical-first-half-2025-earn-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/sichuan-kelun-biotech-biopharmaceutical-first-half-2025-earn-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7104","TTM","06990","BK4523","LU0196878994.USD","TTM.AU","BK1161","BK4099"],"gpt_icon":0},{"id":"1192463629","title":"SKB BIO-B (06990): New Drug Application for A400/EP0031 Accepted by National Medical Products Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=1192463629","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192463629?lang=en_us&edition=fundamental","pubTime":"2025-09-23 07:38","pubTimestamp":1758584298,"startTime":"0","endTime":"0","summary":"SKB BIO-B (06990) announced that a New Drug Application (NDA) for the company's rearranged during transfection (RET) small molecule kinase inhibitor project A400 (also known as EP0031) has been...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2569756435","title":"Sichuan Kelun-Biotech Announces New Drug Application for A400/EP0031 Accepted for Review by China's National Medical Products Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2569756435","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569756435?lang=en_us&edition=fundamental","pubTime":"2025-09-23 07:36","pubTimestamp":1758584214,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Announces New Drug Application for A400/EP0031 Accepted for Review by China's National Medical Products Administration. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief on September 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nNDL3LDkSr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","LU1064130708.USD","002422","LU1934453819.USD","BK0060","LU1064131003.USD","LU1979443071.USD","LU2148510915.USD","06990","BK1161","BK0239"],"gpt_icon":0},{"id":"2569756140","title":"Sichuan Kelun-Biotech Biopharmaceutical - New Drug Application for a400/Ep0031 Accepted for Review by Nmpa China","url":"https://stock-news.laohu8.com/highlight/detail?id=2569756140","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569756140?lang=en_us&edition=fundamental","pubTime":"2025-09-23 07:34","pubTimestamp":1758584073,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nFWN3V90GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2569420411","title":"SKB Biopharma Approves Hong Kong-Listed Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2569420411","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569420411?lang=en_us&edition=fundamental","pubTime":"2025-09-22 16:05","pubTimestamp":1758528330,"startTime":"0","endTime":"0","summary":"Sichuan Kelun-Biotech Biopharmaceutical's  board approved the proposed full circulation of up to nearly 3.6 million domestic shares and over 4.6 million unlisted foreign shares, a Friday Hong Kong bourse filing said.Shares of the drug company were up 2% in Monday afternoon trading.The firm, on the same day, submitted the relevant filing application to the China Securities Regulatory Commission.The company said it will make further announcements as and when needed.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"1124652658","title":"SKB BIO-B (06990) Plans to Implement H-Share Full Circulation Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1124652658","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124652658?lang=en_us&edition=fundamental","pubTime":"2025-09-19 21:06","pubTimestamp":1758287179,"startTime":"0","endTime":"0","summary":"SKB BIO-B (06990) announced that the company's board of directors has reviewed and approved a full circulation plan (H-share full circulation) for certain shareholders' holdings of no more than...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"1156044105","title":"GF Securities: Industry's Medium to Long-term Positive Trend Established, BD Deals Are Just the Starting Point of This Round of Innovative Drug Value Revaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=1156044105","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156044105?lang=en_us&edition=fundamental","pubTime":"2025-09-10 14:18","pubTimestamp":1757485125,"startTime":"0","endTime":"0","summary":"According to analysis, GF Securities released a research report stating that in the first half of 2025, the pharmaceutical industry's operating revenue year-over-year growth rate was -2.3%, with the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","159992","LU0196878994.USD","LU1969619763.USD","LU2328871848.SGD","BK1564","BK0183","LU2097828714.EUR","LU0455707207.USD","BK1147","BK1583","01801","BK1191","03692","01776","LU1979443071.USD","LU2097828805.USD","BK1574","LU0502904849.HKD","000776","LU2488822045.USD","BK0028","BK1593","LU1934453819.USD","LU2097828557.USD","01530","LU2097828474.EUR","LU2097828631.EUR","06990","LU2242644610.SGD","BK0276","BK0188","BK1589","BK0012","BK1161","SG9999001093.SGD"],"gpt_icon":1},{"id":"1197782473","title":"Hong Kong Stock Concept Tracking | MSCI Index Adjustments Take Effect Tomorrow After Market Close! Tech Stocks and Others May Welcome Incremental Funds as Foreign Capital Collectively Turns Bullish on Chinese Assets (With Concept Stocks)","url":"https://stock-news.laohu8.com/highlight/detail?id=1197782473","media":"Stock News","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197782473?lang=en_us&edition=fundamental","pubTime":"2025-08-25 14:47","pubTimestamp":1756104423,"startTime":"0","endTime":"0","summary":"Global renowned index provider MSCI recently announced its August 2025 index review results. These adjustments will take effect after market close on August 26th. Among MSCI's series of indices,...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09899","BK4614","IE0009570106.USD","YANG","LU2265009873.SGD","BK1128","BK1147","HSCEI","BK1615","BK1161","LU0289960550.SGD","TTTN","LU2210150020.SGD","LU0289739343.SGD","06990","LU0708995401.HKD","LU0109391861.USD","LU1804176565.USD","LU0320765059.SGD","03086","BK4112","MSCI","BK1593","LU0511384066.AUD","HSTECH","LU0278937759.USD","01530","LU2210149790.SGD","IE00BKPKM429.USD","LU0289961442.SGD","BK4588","LU0672654240.SGD","LU0175139822.USD","BK1583","LU1267930730.SGD","07226","LU0231459107.USD","BK4585","LU0196878994.USD","LU2095319765.USD"],"gpt_icon":1}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":73,"code":"91000000","status":"200"}]}}